TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23020829
Drug: Selective iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective iron group (n=2142) had screening and treatment for anaemia and a daily intake of 1 mg of folic acid
Study: 20094773
Drug: erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: erlotinib 150 mg/day
Study: 16805715
Drug: Rituximab added
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab added to chemotherapy
Study: 16827869
Drug: TAS (tacrolimus/azathioprine/steroids)
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS (tacrolimus/azathioprine/steroids)
Study: 16827869
Drug: TAS +
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS + B (tacrolimus/azathioprine/steroids/basiliximab)
Study: 12810426
Drug: Epidural corticosteroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural corticosteroid injections (2 ml prednisolone acetate 50 mg)
Study: 12810426
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (2 ml)
Study: 2194466
Drug: ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen plus a rib belt
Study: 7000292
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment (stilboestrol and ethisterone)
Study: 7000292
Drug: Inactive tablets
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablets (control group)
Study: 28074635
Drug: Active arm
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active arm participants received pedometers and recorded step counts with physician monitoring and prescriptions; goal was a 3000 steps/day increase over 1 year.
Study: 28074635
Drug: Active arm
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active arm participants (not treated with insulin)
Study: 21365308
Drug: Resonance frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resonance frequency HRV biofeedback (10 weekly sessions)
Study: 18164106
Drug: Co-administered quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered quadrivalent HPV-6/11/16/18 L1 VLP and HBV vaccines
Study: 12826431
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus platinum chemotherapy
Study: 12826431
Drug: Conventional platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional platinum-based chemotherapy
Study: 10921706
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (200 IU/kg)
Study: 10921706
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (300 IU/kg heparin)
Study: 8888725
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (5.1 g/day)
Study: 1796780
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 1,600 micrograms
Study: 10688033
Drug: HCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG treatment
Study: 17470851
Drug: FLOX (Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOX (Fluorouracil 500 mg/m2 IV bolus weekly for 6 weeks + Leucovorin 500 mg/m2 IV weekly for 6 weeks + Oxaliplatin 85 mg/m2 IV on weeks 1, 3, and 5 for three cycles)
Study: 17470851
Drug: FULV (Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FULV (Fluorouracil 500 mg/m2 IV bolus weekly for 6 weeks + Leucovorin 500 mg/m2 IV weekly for 6 weeks for three cycles)
Study: 15472674
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation with 2 L of polyethylene glycol/electrolyte solution (Group A)
Study: 15472674
Drug: Clear liquids
Normalized name: salicylic acid Medicated Liquid Soap [clear days ahead]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear liquids preparation (Group B)
Study: 11159252
Drug: Epidural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural block with 7 mL 1% lidocaine
Study: 11159252
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of an identical volume of normal saline
Study: 11159252
Drug: IV injection
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection of 1 mg/kg lidocaine
Study: 9355788
Drug: Acetorphan (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetorphan (oral administration prior to cholera toxin)
Study: 2529543
Drug: Acetorphan (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetorphan (oral administration)
Study: 10710119
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg/day)
Study: 3443128
Drug: Molsidomin 8
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomin 8 mg (slow release form)
Study: 3443128
Drug: ISDN 40
Normalized name: ISDN 40 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN 40 mg (slow release form)
Study: 20684724
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of RIX4414
Study: 20684724
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of RIX4414
Study: 20684724
Drug: RIX4414 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 (2 doses and 3 doses)
Study: 10999014
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (1.2 pmol/kg per min)
Study: 8820253
Drug: Inhaled nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitroglycerin (NTG)
Study: 8820253
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (200 mu g MDI) after NTG
Study: 8820253
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (200 mu g MDI) after placebo
Study: 8820253
Drug: FEV1 after
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEV1 after 15 min post-treatment
Study: 1996763
Drug: Lignocaine 10
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 10 mg
Study: 29973970
Drug: Collagen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen (2 ml of collagen MD Muscle)
Study: 29973970
Drug: Lidocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2 ml of 2% lidocaine without a vasoconstrictor)
Study: 29973970
Drug: Saline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2 ml of 0.9% NaCl)
Study: 24094754
Drug: Intoxicating dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intoxicating dose of alcohol (.8 g/kg)
Study: 20530650
Drug: No exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exercise - no treatment (control group, n = 15)
Study: 18826778
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (improved identification, diagnosis, and treatment of depression)
Study: 8970342
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 micrograms twice a day)
Study: 8571641
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of dipyridamole prior to PTCA
Study: 8571641
Drug: Intracoronary dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary dipyridamole infusion during coronary angiography
Study: 384574
Drug: Intra-arterial hepatic
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial hepatic artery infusion with 5-fluorouracil (5-FU)
Study: 384574
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with 5-fluorouracil (5-FU)
Study: 6813477
Drug: Auranofin 2
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin 2 mg daily
Study: 6813477
Drug: Auranofin 6
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin 6 mg daily
Study: 29733414
Drug: ZnAA0 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnAA0 (60 mg Zn/kg from ZnSO4)
Study: 29733414
Drug: ZnAA60 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnAA60 (60 mg Zn/kg from ZnAA)
Study: 29733414
Drug: ZnAA90 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnAA90 (90 mg Zn/kg from ZnAA)
Study: 29733414
Drug: ZnAA120 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnAA120 (120 mg Zn/kg from ZnAA)
Study: 29733414
Drug: ZnAA150 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnAA150 (150 mg Zn/kg from ZnAA)
Study: 29733414
Drug: All ZnAA
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All ZnAA treatments (ZnAA0, ZnAA60, ZnAA90, ZnAA120, ZnAA150)
Study: 22222634
Drug: Perampanel (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (4 mg/d)
Study: 22222634
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg with each dose of L-dopa)
Study: 20574018
Drug: Topical 0.45%
Normalized name: camphor topical 0.45% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.45% OT-551 administered three times daily for 2 years
Study: 16129715
Drug: Forskolin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forskolin (250 mg of 10% forskolin extract twice a day)
Study: 12405362
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g IV as soon as SAH diagnosis was verified, followed by 1 g every 6 hours until aneurysm occlusion, not exceeding 72 hours)
Study: 12405362
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no tranexamic acid treatment)
Study: 7771608
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with AVS
Study: 2124756
Drug: verapamil, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil, 10 mg in 5 minutes (n = 29)
Study: 2124756
Drug: flecainide, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: flecainide, 2 mg/kg in 10 minutes (n = 20)
Study: 2124756
Drug: propafenone, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: propafenone, 2 mg/kg in 10 minutes (n = 20)
Study: 463537
Drug: Induction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of labour by amniotomy and intravenous oxytocin infusion
Study: 30055127
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg daily)
Study: 25623736
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation plus standard treatment
Study: 18401974
Drug: Single intravaginal
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravaginal dose of Polyhexamethylene Biguanide (PHMB)
Study: 18401974
Drug: Seven daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven daily doses of Clindamycin vaginal cream
Study: 18401974
Drug: Single intravaginal
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravaginal dose of Polyhexamethylene Biguanidine (PHMB)
Study: 11198264
Drug: 5,000 mg
Normalized name: garlic 5,000 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 mg ascorbic acid
Study: 11198264
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (all doses)
Study: 9160496
Drug: Treatment among
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment among compliers
Study: 8416762
Drug: Amlodipine 2.5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5‐10 mg once daily
Study: 8416762
Drug: Nadolol 40‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 40‐160 mg once daily
Study: 31513531
Drug: Xyla-P cream
Normalized name: capsaicin Topical Cream [Capzasin-P]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xyla-P cream
Study: 23559222
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg oral yohimbine
Study: 15901043
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg twice daily, n = 7)
Study: 15901043
Drug: Carvedilol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5 mg once daily for two days and thereafter 25 mg daily, n = 7)
Study: 15901043
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg once daily, n = 6)
Study: 12687534
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg daily by subcutaneous injection)
Study: 8635937
Drug: Olsalazine 250
Normalized name: olsalazine 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine 250 mg, two capsules twice daily
Study: 8635937
Drug: Placebo, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two capsules twice daily
Study: 1615937
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (blood transfusions, antacids, and ranitidine) (group 2)
Study: 25316469
Drug: Regular intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intermittent bolus (RIB) - 10 ml of 0.08% ropivacaine + 0.4 ug·ml‐1 sufentanil administered once an hour
Study: 25316469
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) - same solution continuously infused at a rate of 10 ml·h‐1
Study: 10410207
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (diaphragm breathing with incentive spirometry and postural drainage)
Study: 10410207
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (diaphragm breathing with positive expiratory pressure (PEP-mask) and postural drainage)
Study: 30077350
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg intravenous ibuprofen in 100 mL saline solution
Study: 30077350
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL intravenous saline solution
Study: 28007113
Drug: Steroid (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (prednisolone acetate 1.0% [Pred Forte])
Study: 15816575
Drug: Remifentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil TCI with initial effect site concentration of 1.5 ng mL(‐1)
Study: 15816575
Drug: Fentanyl TCI
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl TCI with initial effect site concentration of 2 ng mL(‐1)
Study: 9771182
Drug: 15 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 micrograms (0.3 ml) fentanyl added to 2.5 ml 0.5% hyperbaric bupivacaine
Study: 9771182
Drug: 0.3 ml
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml 0.9% saline (control group)
Study: 29482525
Drug: Internet-based grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based grief therapy
Study: 24713286
Drug: Compound whole
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound whole grain-soybean
Study: 20575206
Drug: Transbond CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transbond CC
Study: 17012900
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine plus SRL 172
Study: 17012900
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine plus placebo
Study: 8936627
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg daily
Study: 8936627
Drug: Chlormadinone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone 50 mg daily
Study: 8936627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tamsulosin 0.2 mg and chlormadinone 50 mg daily
Study: 8936627
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg and chlormadinone 50 mg daily
Study: 24116868
Drug: Ustekinumab dose
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab dose adjustment to 90 mg
Study: 18220486
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg b.i.d.
Study: 7294327
Drug: Physostigmine 2
Normalized name: PHYSostigmine 2 mg/5 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 2 mg
Study: 15819761
Drug: Nefopam 10
Normalized name: nefopam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 10 mg
Study: 8951965
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (0.1 mg/70 kg)
Study: 8951965
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.5, 1, and 2 mg per 70 kg) with fentanyl
Study: 1937995
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg intravenously every 8 hours for 3 days, then 150 mg orally in the evening for one month)
Study: 7380586
Drug: Proquazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proquazone (600 mg) after 20 ml of antacid (Maaloxan)
Study: 7380586
Drug: Proquazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proquazone (600 mg) after a standard breakfast
Study: 31763228
Drug: Lipid based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid based ointment with tablet Rupatidine 10 mg OD
Study: 31763228
Drug: Tablet Rupatidine
Normalized name: ROXATIDINE
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Rupatidine 10 mg OD alone
Study: 17051119
Drug: Control areas
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control areas (no treatment)
Study: 11078252
Drug: Intravenous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ethanol administration (60 ml of 100 proof ethanol)
Study: 1526058
Drug: Aerosol spray
Normalized name: Betadine Aerosol Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol spray (Otomize)
Study: 29984804
Drug: Fibroblast growth
Normalized name: Fibroblast growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibroblast growth factor‐2 treatment
Study: 25663125
Drug: CF-HAIC (Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF-HAIC (Cisplatin 60 mg/m2 on day 2, 5-FU 500 mg/m2 on days 1-3)
Study: 25663125
Drug: ACF-HAIC (Adriamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACF-HAIC (Adriamycin 50 mg/m2 on day 1, Cisplatin 60 mg/m2 on day 2, 5-FU 500 mg/m2 on days 1-3)
Study: 22027669
Drug: Topamax (topiramate)
Normalized name: topiramate Oral Tablet [Topamax]
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topamax (topiramate) as mono-therapy (8 children) and combined therapy (22 children) with a mean treatment dose of 5.9 mg/kg per day
Study: 17485058
Drug: Conventional gauze
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional gauze therapy
Study: 16619056
Drug: Oxyntomodulin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxyntomodulin administration
Study: 14508884
Drug: MBI-226 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBI-226 gel formulation
Study: 9187996
Drug: Triiodothyronine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine (4 x 10(‐12) to 1 x 10(‐4) mol/L)
Study: 9187996
Drug: Triiodothyronine (10(‐9)
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triiodothyronine (10(‐9) to 10(‐8) mol/L)
Study: 1568371
Drug: Single i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. administration of 2 g ceftazidime concurrent with anesthesia induction (group 1)
Study: 1568371
Drug: Short-term prophylaxis
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term prophylaxis with 1 g ceftazidime administered preanesthesia, 30 min before surgery and 6 and 12 hrs after the first dose (group 2)
Study: 2859775
Drug: Acebutolol 100
Normalized name: acebutolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 100 mg three times a day
Study: 2859775
Drug: Acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 200 mg three times a day
Study: 2859775
Drug: Acebutolol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 600 mg three times a day
Study: 2859775
Drug: Propranolol 30
Normalized name: HCTZ 25/PROPRANOLOL 30MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 30 mg three times a day
Study: 2859775
Drug: Propranolol 60
Normalized name: propranolol 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 60 mg three times a day
Study: 2859775
Drug: Propranolol 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 180 mg three times a day
Study: 2859775
Drug: Acebutolol 1
Normalized name: acebutolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 1 mg/kg infused over 15 minutes
Study: 20980998
Drug: Twice-weekly kisspeptin-54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly kisspeptin-54 (KP-54) injections for 8 weeks